Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.

Medtronic’s investment is contingent on Anteris completing a proposed $200 million public stock offering.

Anteris Technologies says Medtronic will make a strategic investment of up to $90 million in the transcatheter heart valve ...

Several medical societies supported extending Medicare coverage for TAVR to patients with asymptomatic aortic stenosis, but ...

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...

Medtronic plc acted on the increase in M&A and expansion of its investment ecosystem touted at the J.P. Morgan Healthcare Conference earlier this month with a $90 million infusion into Brisbane, ...

The latest generation of Medtronic’s transcatheter aortic valve replacement implant has passed the FDA’s muster. Like those that came before it, the new Evolut FX+ is placed through a minimally ...

The Medtronic investment and the underwritten public offering of common stock position Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform ...

Revised Commercial Labeling Broadens Patient Population Who May be Candidates for Transcatheter Aortic Valve Replacement (TAVR) DUBLIN, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the ...

Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...

Medtronic is pumping up its activation of heart valve disease patients. The company has partnered with an advocacy group for heart valve disease, Heart-Valve-Surgery.com, to create a digital platform ...

Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...